Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 279 Carboplatin 214 Cisplatin 145 Gemcitabine 144 Paclitaxel 142 Bevacizumab 115 Pemetrexed 112 Docetaxel 100 Oxaliplatin 78 Dexamethasone 77 durvalumab 76 Fluorouracil 76 atezolizumab 75 Nivolumab 74 Cyclophosphamide 74 130-nm albumin-bound paclitaxel 71 Fulvestrant 68 Cetuximab 63 Capecitabine 63 Injections 61 Leucovorin 60 Rituximab 55 fludarabine 50 Lenalidomide 49 venetoclax 43 Prednisone 43 Irinotecan 42 enzalutamide 39 Letrozole 39 tislelizumab 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sulfonylurea Compounds × 90 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡